Evidence map›Paper›PMID 23420659›Full record

ArticleThe Journal of physiology2013

Genetic removal of basal nitric oxide enhances contractile activity in isolated murine collecting lymphatic vessels.

Joshua P Scallan, Michael J Davis

Open access · greenAbstract read
In one paragraph

Article in The Journal of physiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 119 citations in OpenAlex.

  1. Article
  2. Review
  3. Pacemaking in the lymphatic system.The Journal of physiology · 2026
    Review
  4. Guidelines for evaluating endothelial function in vascular tissue.American journal of physiology. Heart and circulatory physiology · 2026
    Review
  5. Article
  6. Article
  7. Regulation of Collecting Lymphatic Vessel Contractile Function by TRPV4 Channels.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Molecular pathophysiology of secondary lymphedema.Frontiers in cell and developmental biology · 2024
    Review
  13. Review
  14. Topical captopril: a promising treatment for secondary lymphedema.Translational research : the journal of laboratory and clinical medicine · 2023
    Article
  15. Article
  16. KAmerican journal of physiology. Cell physiology · 2022
    Review
  17. Lymphatic Vascular Permeability.Cold Spring Harbor perspectives in medicine · 2022
    Review
  18. Article
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Joshua P ScallanDepartment of Medical Pharmacology & Physiology, University of Missouri School of Medicine, Columbia, MO 65212, USA.
Michael J Davis
University of Missouri · US

Funding

Cellular Mechanisms of Lymphatic Muscle ContractilityR01HL089784 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI DAVIS, MICHAEL JOHN · 2008 to 2012
$1.7M
NHLBI NIH HHS HL-089784NHLBI NIH HHS R01 HL089784
6 · The paper itself

Abstract

The role of nitric oxide (NO) in regulating lymphatic contractile function and, consequently, lymph flow has been the subject of intense study. Despite this, the precise effects of NO on lymphatic contractile activity remain unclear. Recent hypotheses posit that basal levels of endogenous NO increase lymphatic contraction strength as a consequence of lowering frequency (i.e. positive lusitropy), whereas higher agonist-evoked concentrations of NO exert purely inhibitory effects on contractile function. We tested both hypotheses directly by isolating and cannulating collecting lymphatic vessels from genetically modified mice for ex vivo study. The effects of basal NO and agonist-evoked NO were evaluated, respectively, by exposing wild-type (WT), endothelial NO synthase (eNOS)(-/-) and inducible NO synthase (iNOS)(-/-) lymphatic vessels to controlled pressure steps followed by ACh doses. To compare with pharmacological inhibition of eNOS, we repeated both tests in the presence of l-NAME. Surprisingly, genetic removal of basal NO enhanced contraction amplitude significantly without increasing contraction frequency. Higher levels of NO production stimulated by ACh evoked dilation, decreased tone, slowed contraction frequency and reduced fractional pump flow. We conclude that basal NO specifically depresses contraction amplitude, and that greater NO production then inhibits all other aspects of contractile function. Further, this work demonstrates definitively that mouse collecting lymphatic vessels exhibit autonomous, large-amplitude contractions that respond to pressure similarly to collecting lymphatics of other mammalian species. At least in the peripheral lymphatic vasculature, NO production depresses contractile function, which influences lymph flow needed for fluid regulation, humoral immunity and cancer metastasis.

Indexed as

AnimalsEnzyme InhibitorsLymphatic VesselsMaleMiceMice, Inbred C57BLMice, KnockoutNG-Nitroarginine Methyl EsterNitric OxideNitric Oxide Synthase Type IINitric Oxide Synthase Type IIIEnzyme InhibitorsNG-Nitroarginine Methyl EsterNitric OxideNitric Oxide Synthase Type IINitric Oxide Synthase Type IIINos2 protein, mouseNos3 protein, mouse

Identifiers

PMID23420659
PMCPMC3634525
OpenAlexW2132454600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.